PNC Financial Services Group
CADL icon

PNC Financial Services Group’s Candel Therapeutics CADL Stock Holding History

PNC Financial Services Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$754 Buy
154
+149
+2,980% +$811 ﹤0.01% 4817
2025
Q4 		$28 Sell
5
-59
-92% -$317 ﹤0.01% 5121
2025
Q3 		$326 Buy
+64
New +$370 ﹤0.01% 4877

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PNC Financial Services Group's CADL Position: Q1 2026 in Review

PNC Financial Services Group increased its Candel Therapeutics (CADL) stake by 2,980% in Q1 2026, buying an estimated $811 and bringing the position to 154 shares worth $754. The position accounts for ﹤0.01% of the portfolio, ranked #4817.

PNC Financial Services Group first reported a position in CADL in Q3 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • PNC Financial Services Group held 154 shares of Candel Therapeutics worth $754 as of Q1 2026.
  • PNC Financial Services Group bought 149 Candel Therapeutics shares in Q1 2026, an estimated $811.
  • Candel Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4817 holding.
  • PNC Financial Services Group first reported a position in Candel Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.